University of Groningen, Netherlands
Microalbuminuria screening may predict chronic kidney disease and cardiovascular disease risk
Published in Pharma Law Weekly, July 18th, 2006
"The incidence of end stage renal disease in patients who have not experienced a classic primary renal disease is dramatically increasing. Chronic kidney disease (CKD) in these patients is due to diabetes, mostly type 2, hypertension and generalized atherosclerosis," investigators in Netherlands report in their review.
"As these patients are frequently diagnosed as having renal function impairment only in the late phase, more effort should be undertaken to diagnose them earlier, that is, at a time when renoprotective measures can...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2006-07-18)
More Articles from Pharma Law Weekly
- Alnylam
Alnylam reports positive outcome in European proceedings on Kreutzer-Limmer I patent - Clarient
Clarient signs agreement to purchase assets of Trestle Holdings, Inc. - Cobalis
Cobalis' E.U. patent for PreHistin becomes effective - Fitch Ratings
Fitch revises Schering-Plough Corp.'s Rating Outlook to Stable, affirms 'A-/F2' - Groningen University, Netherlands
More patients switch to another proton pump inhibitor after omeprazole patent expiry - Healthcare Costs
A new survey released finds that Medicare prescription drug plans are paying pharmacists promptly - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
